Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AllerT Efficacy in Birch Pollen Allergy
NCT01720251Phase 2Completed
- Sponsor
- Anergis
- Start
- Oct 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of cetirizine in allergic rhinoconjunctivitis (ARC), sponsored by Anergis. Started Oct 2012; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01720251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720251.